Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PharmadrugLMLLF +84.00% 3-Year EPS without NRI Growth Rate is 53.60% as of Mar. 2026, which is 14% above its 10-year median of 46.90. The stock has 1 warning sign investors should review. Among 785 Drug Manufacturers companies, Pharmadrug ranks better than 88.66% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 53.60% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 50.50% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 37.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Pharmadrug was 57.80% per year. The lowest was -19.40% per year. And the median was 46.90% per year.
Pharmadrug (OTCPK:LMLLF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Pharmadrug 3-Year EPS without NRI Growth Rate Related Terms
LMLLF vs ZTS: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pharmadrug's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmadrug 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pharmadrug's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Pharmadrug's 3-Year EPS without NRI Growth Rate falls into.
Pharmadrug 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 53.60% mean?
Pharmadrug (LMLLF) has a 3-Year EPS without NRI Growth Rate of 53.60% as of Mar. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Pharmadrug and its competitors. This is 14% above median its historical median of 46.90. According to the industry distribution chart, Pharmadrug ranks #89 out of 785 companies in the Drug Manufacturers industry, placing it in the top 11.3%.
Is Pharmadrug's 3-Year EPS without NRI Growth Rate too high?
Pharmadrug's current 3-Year EPS without NRI Growth Rate of 53.60% is 14% above median its 10-year median of 46.90. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.60. Pharmadrug's value of 53.60% is 458.3% above this industry median. Based on the distribution chart, Pharmadrug ranks #89 out of 785 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Pharmadrug's 3-Year EPS without NRI Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Pharmadrug ranks #89 out of 785 companies for 3-Year EPS without NRI Growth Rate. This places Pharmadrug in the top 11% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 9.60. Pharmadrug's value of 53.60% is 458.3% above this benchmark. While the company's 10-year median is 46.90 vs. the industry median of 9.60, Pharmadrug has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.60, based on 785 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmadrug's current 3-Year EPS without NRI Growth Rate of 53.60% is 458.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Pharmadrug and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmadrug's current 3-Year EPS without NRI Growth Rate is 53.60%, which is 14% above median its own 10-year median of 46.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmadrug stock overvalued right now?
Based on GuruFocus' analysis, Pharmadrug (LMLLF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.04, compared to a current price of $0.01 — trading 83.9% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 53.60%, which is 14% above median its 10-year median of 46.90 and 458.3% above the Drug Manufacturers industry median of 9.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Pharmadrug (LMLLF), the current 3-Year EPS without NRI Growth Rate is 53.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pharmadrug Inc is a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and naturally derived approved drugs. The company's operations comprise of the corporate division in Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LMLLF has been successfully added to your 
